[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,40,68,96,116,135,161,185],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100602238","augmented-reality-real-time-guidance-for-mri-guided-interventions-100602238",false,"NCT07120906","Augmented Reality Real-Time Guidance for MRI-Guided Interventions","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, ages 18-90 years\n* Patient referred to Interventional Radiology for image-guided liver needle placement for ablation\u002Fbiopsy.\n\nExclusion Criteria:\n\n* Patients who are unable to give informed consent themselves or through their parents.\n* Patients that do not fit into MR scanner (70 cm bore) with room for needle placement.\n* Contraindications to MRI such as MR-unsafe implants.","ALL","18 Years","90 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this research is to evaluate the safety and feasibility of using a needle guidance system (LUMENA) create by CLEAR GUIDE MEDICAL for needle placement for biopsy or liver tumor ablation procedures.",[26],"Liver","RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-26","ACTUAL",{"date":33,"type":31},"2025-07-25",{"date":35,"type":20},"2026-12-31",{"name":37,"class":38},"Mayo Clinic","OTHER",2,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100641430","international-delphi-study-to-develop-standardized-quality-criteria-and-a-rating-tool-for-liver-ceus-image-quality-assessment-100641430","NCT07656181","International Delphi Study to Develop Standardized Quality Criteria and a Rating Tool for Liver CEUS Image Quality Assessment","Delphi Study on Quality Indicators for CEUS Imaging of the Liver Using SonoVue® Contrast Agent","ICON LiverCEUS","Inclusion Criteria:\n\n* At least 6 years of active experience in ultrasound diagnostics in internal medicine, radiology, or a related clinical field\n* Independent performance of at least 5,000 ultrasound examinations Participation in structured CEUS training\n* Performance of at least 800 ultrasound examinations per year in routine clinical practice\n* Either: at least 100 independently performed CEUS examinations per year or more than 700 CEUS examinations in total\n* Regular participation in ultrasound-related meetings, case reviews, or quality assurance activities within their institution\n* Scientific involvement in CEUS, demonstrated by at least one peer-reviewed publication and\u002For active engagement in CEUS education or training\n* Signing the consent form of the participants\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria",true,{"count":50,"type":20},35,"OBSERVATIONAL","This study aims to establish international consensus-based quality criteria for contrast-enhanced ultrasound (CEUS) examinations of the liver and to develop a standardized tool for assessing CEUS image quality. CEUS is an established imaging technique used in clinical practice for the characterization and assessment of focal liver lesions and other liver abnormalities. Despite its increasing use, there are currently no universally accepted or validated standards for evaluating the quality and reproducibility of CEUS examinations.\n\nThe primary objective of this project is therefore to identify robust and clinically relevant quality indicators for liver CEUS examinations through an international Delphi consensus process. The study focuses specifically on CEUS examinations performed in adult patients using the ultrasound contrast agent SonoVue®.\n\nThe project is divided into two work packages (WP). In Work Package 1 (WP1), the study team will first conduct a structured review of the available literature and discuss potential CEUS quality criteria within the research group. Based on this process, an initial catalogue of quality indicators relating to technical, procedural, and imaging characteristics relevant to liver CEUS examinations will be developed.\n\nThese proposed criteria will subsequently be evaluated through a multi-round Delphi process involving an international and interdisciplinary panel of experienced CEUS users and experts. A minimum of 20 panellists will participate across all Delphi rounds. Participants will rate their level of agreement with each proposed quality criterion using a 7-point Likert scale and may suggest additional criteria where appropriate. Newly proposed criteria supported by more than 10% of participants will be included in subsequent Delphi rounds.\n\nDuring each round, panellists will receive anonymised feedback summarising the responses of the group and will be invited to re-evaluate the relevance of the proposed criteria. This iterative process will continue for at least three rounds or until predefined consensus criteria are achieved. Consensus will be defined as at least 70% agreement with a rating of 6 or higher on the Likert scale.\n\nIn Work Package 2 (WP2), the consensus-based quality criteria identified in WP1 will be operationalised into a comprehensive and standardized rating scale for CEUS image quality assessment. Individual criteria will be grouped into broader domains and transformed into practical assessment items and prompts. The resulting rating tool will then be circulated among all Delphi panel members for final review and feedback to ensure clarity, applicability, and international usability.\n\nThe overall goal of this study is to improve standardization, quality assurance, and reproducibility in liver CEUS examinations. The developed consensus criteria and rating scale may support clinical practice, future research studies, multicentre collaborations, and educational initiatives by enabling more consistent evaluation of CEUS image quality across institutions and countries.",[54,55,26],"Contrast Enhanced Ultrasound","Ultrasonic Diagnosis",[57],"Quality Indicators of Liver CEUS","2026-06-22",{"date":60,"type":31},"2026-06-25",{"date":62,"type":20},"2026-06-01",{"date":64,"type":20},"2026-09-30",{"name":66,"class":38},"University of Bern",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100641506","development-of-a-predictive-score-for-the-risk-of-infection-in-the-immediate-post-liver-transplant-period-100641506","NCT07647978","Development of a Predictive Score for the Risk of Infection in the Immediate Post-liver-transplant Period","PREDITH","Inclusion Criteria:\n\nPatients awaiting liver transplantation for one of the following indications:\n\n* Compensated cirrhosis complicated by hepatocellular carcinoma\n* Chronically decompensated cirrhosis (recurrent gastrointestinal bleeding, refractory ascites, portopulmonary or hepatopulmonary syndrome, hepatic encephalopathy, chronic liver failure)\n* Acute decompensated cirrhosis, with or without associated multiple organ failure (ACLF)\n* Acute fulminant hepatitis\n\nFinal inclusion will be :\n\n* Patients receiving LT AND\n* Who provided their consent to participate during the initial enrollment visit AND\n* For whom the baseline sample (during the day of the LT) was collected\n\nExclusion Criteria:\n\n* Minors\n* Patients under legal guardianship or conservatorship\n* Pregnant or breastfeeding women\n* Patients deprived of their liberty\n* Patients not enrolled in the social security system\n* Refusal to participate in the study\n* Patients receiving immunosuppressive therapy prior to LT (with the exception of corticosteroids at a dosage of 40 mg per day for the treatment of alcoholic hepatitis)\n* Patient who is a candidate for a combined organ transplant\n* Patient receiving other immunomodulatory therapy (such as immune checkpoint inhibitors) prior to LT",{"count":76,"type":20},279,"Liver transplantation (LT) is the only curative treatment option for patients with severe liver disease. Since 2007, the implementation of the MELD score in liver transplant allocation guidelines has led to a change in the profile of transplant recipients, notably with an increase in the proportion of patients receiving transplants for severe liver failure. Thus, in 2023, nearly 40% of liver transplant recipients whose primary indication for LT was cirrhosis had a MELD score greater than 35 (ABM Scientific Report 2023). These patients with severe pre-transplant liver failure often present with associated organ failure (Acute-on-Chronic Liver Failure, ACLF). Infections are the leading cause of death at 1 year post-transplant for patients transplanted with ACLF and are a major concern for all patients, representing one of the leading causes of death at 3 months post-transplant. Another common complication following LT is acute cellular rejection. Although frequent, this complication is reversible with treatment and results in graft loss in fewer than 5% of cases.\n\nThe expression of the HLA-DR marker by monocytes (mHLA-DR) is correlated with immunoparesis and the risk of secondary infection and mortality in patients admitted to critical care. In a prospective, single-center pilot study of 99 liver transplant recipients, the Hepatology and Gastroenterology service at the Croix Rousse Hospital, Hospices Civils de Lyon, demonstrated that the kinetics of mHLA-DR levels measured immediately after transplantation could predict the risk of early significant infection (\\\u003C 1 month) after transplantation and 1-year post-transplant mortality. The early post-transplant kinetics of mHLA-DR expression recovery appeared to be a more relevant predictor of the risk of early post-transplant infection than a single-point-in-time value. The profile of immune recovery kinetics, as well as a pre-LT MELD score \\> 30, were associated in multivariate analysis with the risk of developing an infection at 1 month post-LT and with 1-year post-LT survival.\n\nPREDITH study team hypothesize that the implementation of mHLA-DR testing immediately post-LT would enable the development of a predictive score for early post-LT infection combining clinical and biological risk factors for post-LT infection and immune monitoring.",[79,80,26,81],"Cirrhosis","Acute Hepatitis","mHLA-DR",[83,81,79,84],"liver","Acute hepatitis","NOT_YET_RECRUITING","2026-06-15",{"date":88,"type":31},"2026-06-17",{"date":90,"type":20},"2026-07-01",{"date":92,"type":20},"2030-07-01",{"name":94,"class":38},"Hospices Civils de Lyon",3,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":67},"100506805","accelerated-recovery-after-mis-hepatectomy-aramis-hep-to-support-early-discharge-for-patients-undergoing-minimally-invasive-liver-resection-100506805","NCT05879159","Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection","Inclusion Criteria:\n\n* Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below)\n* No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results)\n* No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection\n* Ability to stay within 50 miles of medical center for immediate postop period\n* Age of 18 years or above - because no adverse event data are currently available on enhanced recovery and early discharge after hepatic resection for patients \\\u003C18 years of age, children are excluded from this study\n* Ability to understand and the willingness to sign a written informed consent document\n* Non-English-speaking patients are eligible for participation\n\nExclusion Criteria:\n\nPatients who will be excluded include those with:\n\n* Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy\n* Tumors not amenable to MIS or Robotic-assisted surgical resection\n* Evidence of Cirrhosis on imaging, clinically, or lab testing\n* Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period\n* Age below 18 years\n* Inability to consent for trial\u002Fprotocol\n* Patients who are pregnant",{"count":103,"type":20},36,[23],"To learn if an accelerated recovery program can shorten the length of hospital stay in patients having minimally invasive liver surgery.",[26],"2026-04-13",{"date":109,"type":31},"2026-04-15",{"date":111,"type":31},"2023-10-05",{"date":113,"type":20},"2027-02-01",{"name":115,"class":38},"M.D. Anderson Cancer Center",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":67},"100627131","predictt-clinical-trial-prospective-evaluation-of-pressure-enabled-delivery-and-alterations-in-ct-based-tumor-to-normal-liver-ratio-and-tumor-dose-using-the-trinav-infusion-system-100627131","NCT07444645","PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System","Inclusion Criteria:\n\n1. Patients over 18 years of age, of any race or sex, who have unresectable primary or metastatic tumors of the liver, and who are able to give informed consent\n2. Patients must be eligible for Y90-radioembolization treatment, have an ECOG Performance Status score of ≤ 2, with a life expectancy of ≥ 3 months\n3. At least one lesion ≥ 3.0 cm in shortest dimension\n4. Negative pregnancy test in premenopausal women with an acceptable contraception\n5. Plan to perform bilobar, lobar or sectoral treatment using partition dosimetry\n6. Evidence of partial or complete tumor vascularity based on pre-procedure liver protocol CT scan or MRI with contrast or intraprocedural hybrid angio CT as well as subjectively similar tumor vascularity between right and left lobes if bilobar treatment is planned\n7. Right or left hepatic artery diameter of 1.5 mm to 5 mm (the recommended vessel size range for the TriNav Infusion System) based on pre-procedure arterial phase CT or intraprocedural hybrid angio CT\n\nExclusion Criteria:\n\n1. Contraindications to angiography and selective visceral catheterization\n2. Evidence of potential delivery of greater than 30 Gy absorbed dose to the lungs with a single treatment session\n3. CT based TNR of 3 or higher based on planning hybrid angioCT\n4. Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow (eg, placing catheter distal to gastric vessels)\n5. Infiltrative tumors",{"count":19,"type":20},[23],"This single-arm prospective study will compare CT-based tumor-to-normal ratio (TNR) measurements obtained using TriNav versus endhole microcatheters.",[126,26],"Tumor","2026-02-26",{"date":129,"type":31},"2026-03-03",{"date":131,"type":20},"2026-08-01",{"date":133,"type":20},"2030-07-31",{"name":115,"class":38},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":67},"100615823","3d-liver-volumetry-100615823","NCT07297615","3D Liver Volumetry","Accuracy of Individualized 3D Reconstruction in Predicting Liver Resection Volume: A Prospective Study","Inclusion Criteria:\n\n* Adult patients (≥18 years) undergoing open or minimally invasive major liver resection at the Clinical Division of General, Visceral and Transplant Surgery who provide written informed consent prior to participation will be included.\n\nExclusion Criteria:\n\n* Patients unable to provide informed consent will be excluded.\n* Minor resections.\n* Contraindications to MRI.",{"count":143,"type":20},25,[23],"The study aims to improve preoperative evaluation of liver resection volume in patients undergoing major hepatectomies. Accurate prediction of the planned resection and the future liver remnant (FLR) is critical to minimize the risk of postoperative liver failure, which is associated with increased morbidity and mortality. Conventional imaging-based volumetry may have limited accuracy. This study investigates the use of individualized 3D liver models combined to enhance visualization and volumetric analysis of liver anatomy and resection boundaries.\n\nPatients are recruited in the liver outpatient clinic and, upon consent, preoperative 3D models are created using Medics 3D. During surgery, the planned resection is guided by the individualized 3D models. Postoperatively, the resected specimen undergoes CT-based volumetry to compare the predicted resection volume from the 3D model with the actual volume. Routine postoperative follow-up is conducted. The study aims to optimize surgical planning, enhance the accuracy of future liver remnant prediction.",[147,148,149,26,150,151],"Liver Surgery","Liver Cancer","Surgical Planning","Volumetric Analysis","3D-reconstruction","2026-02-13",{"date":154,"type":31},"2026-02-17",{"date":156,"type":20},"2026-04-01",{"date":158,"type":20},"2028-09-30",{"name":160,"class":38},"Medical University of Graz",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":39},"100559238","the-gastric-bypass-stent-system-as-a-treatment-for-hepatic-fibrosis-in-obese-patients-in-european-region-100559238","NCT06561529","The Gastric Bypass Stent System as a Treatment for Hepatic Fibrosis in Obese Patients in European Region","A Prospective, Open-label, Single-arm Clinical Study to Evaluate the Safety and Performance of the Gastric Bypass Stent System as a Treatment for Hepatic Fibrosis in Obese Patients in European Region","Subjects who meet all of the following criteria are eligible for this clinical investigation:\n\n1. Age 18-65 years.\n2. BMI ≥ 30 kg\u002Fm².\n3. Medical history suggests suspected or confirmed NASH fibrosis. Meeting any of the following criteria indicates NASH liver fibrosis:\n\n   * Historical biochemical tests for fibrosis: PRO-C3 \\>14 ng\u002FmL or ELF ≥9\n   * Fibroscan, transient elastography ≥8.5 kPa, controlled attenuation parameter ≥280 dB\u002Fm\n   * Based on existing pathology review, liver biopsy within \\\u003C2 years before the expected randomization shows stage 1B, 2, or 3 fibrosis NASH, with no significant weight change \\>5% or medications likely affecting NAS or fibrosis stage.\n4. Liver biopsy confirming NASH within 6 months before the randomization date, with liver biopsy fibrosis stage 1-3, NAS ≥3, and at least a score of 1 for the following NAS components:\n\n   * Steatosis (0-3 points)\n   * Ballooning (0-2 points)\n   * Lobular inflammation (0-3 points)\n5. Patients who have not achieved effective results after three months of lifestyle modifications and non-invasive treatments (non-diabetic patients have not achieved a weight loss of 5%, diabetic patients have not achieved a weight loss of 3%).\n6. Able and willing to provide informed consent for participation in the clinical investigation and comply with all study procedures and assessments.\n\nSubjects who meet any of the following criteria are not eligible for this clinical investigation:\n\n1. Patients with liver cirrhosis\n2. Patients with secondary obesity; a medical condition that has caused weight gain such as endocrine disorders and hypothalamic disorders.\n3. Chronic, daily use of systemic anti-inflammatory or corticosteroid medications (e.g., ibuprofen, prednisolone) for more than 1 week (not including low-dose aspirin for cardiac prophylaxis or inhaled corticosteroids).\n4. Patients with less than one-year continuous treatment before baseline with hypoglycemic drugs with known weight loss effects (e.g., GLP-1 agonists, SGLT-2 inhibitors, DDP-4 inhibitors).\n5. Patients diagnosed with type 1 diabetes.\n6. Patients with the function of islet β cell basically lost, C-peptide ≤ 1\u002F2 of the normal low limit, or low and flat C-peptide release curve under glucose load.\n7. Patients with significant iron deficiency or iron deficiency anemia upon the Investigator's discretion.\n8. Patients with coagulation dysfunction and chronic, daily use of systemic anti-inflammatory or anti-coagulation medication in the past month (not including low-dose aspirin).\n9. Patients with severe liver and kidney dysfunction, and a serum creatinine concentration ≥ 180 μmol\u002FL.\n10. Patients with Class III heart function of New York Heart Association Functional Classification (NYHA) or higher upon the Investigators evaluation.\n11. Patients who have undergone Endoscopic Retrograde Cholangiopancreatography (ERCP) or have a history of cholecystitis or liver abscess, as assessed by medical history and abdominal ultrasound.\n12. Patients with a duodenal ulcer, gastric ulcer, or previous and existing pancreatitis, as assessed by abdominal ultrasound, gastroscopy (prior to the procedure at Visit 3), and medical history.\n13. Patients with gallstones (diameter ≥ 20 mm) with clinical symptoms as assessed by abdominal ultrasound and medical history.\n14. Patients with on-going thyroid dysfunction, not stabilized despite appropriate treatment.\n15. Patients with hemorrhage or potential hemorrhage in the digestive tract.\n16. Patients with gastrointestinal tract anomalies, such as gastrointestinal tract atresia, or other conditions that would result in failed placement in the gastrointestinal tract, as assessed by gastroscopy (prior to the procedure at Visit 3), abdominal digital gastrointestinal radiography, and medical history.\n17. Patients with a history of bowel obstruction or related diseases in the past year.\n18. Patients with a history of systemic lupus erythematosus or scleroderma.\n19. Patients with severe infections that are not controlled.\n20. Patients with poor general condition and having endoscopic contraindications (as evaluated by the Investigator).\n21. Pregnant women or planning to become pregnant.\n22. Patients with an alcohol dependence or substance abuse.\n23. Patients with unstable psychiatric disorders.\n24. Patients who are enrolled in another investigational study and have not completed the required follow-up period.\n25. Patients with an allergy to any of the components of the investigational device.\n26. Patients with any other conditions evaluated by the Investigators as unsuitable for participating in the clinical investigation.\n27. Patients who are positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus as determined by antibodies, deoxy\u002Fribonucleic acid (DNA\u002FRNA), or antigens.\n\nNote: Anti-HCV positive, but HCV-RNA negative HCV patients can be included, based on investigator's judgement, if it's not the primary reason for the fibrosis. Anti-HBc positive, but HBs-Ag negative patients can be included, based on investigator's judgement.","65 Years",{"count":170,"type":20},10,[23],"The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity and holds potential as a non-invasive technique for managing hepatic fibrosis. This pilot, prospective, single-arm, clinical investigation aims to evaluate the safety and performance of the Gastric Bypass Stent System for hepatic fibrosis treatment in Europe. This clinical investigation and the ongoing clinical investigation (Protocol number: BL-RD08-040) will be used to evaluate the safety and performance of the investigational device for the intended use.",[174,26],"Fibrosis","2025-05-06",{"date":177,"type":31},"2025-05-08",{"date":179,"type":31},"2024-06-13",{"date":181,"type":20},"2025-12",{"name":183,"class":184},"MDCECRO LLC","NETWORK",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":205,"locationsCount":4},"100527911","salt-for-patients-with-hepatic-cirrhosis-100527911","NCT06153914","SALT for Patients With Hepatic Cirrhosis","A Clinical Study of the Effectiveness of Sequential Adult Left Lateral Lobe Liver Transplantation in Patients With Hepatitis B Cirrhosis: a Single-center, Prospective, Single-arm Study","Inclusion Criteria:\n\n* ①Age 18-75 years old;\n\n  * Have a history of hepatitis B infection;\n\n    * The imaging results are consistent with the manifestations of liver cirrhosis;\n\n      * One of the following conditions: Meld score 15-40 points, esophageal and gastric variceal bleeding, refractory ascites, recurrent hepatic encephalopathy, hepatorenal syndrome, or hepatopulmonary syndrome; ⑤PS score 0-1 points; ⑥Sign the informed consent form.\n\nExclusion Criteria:\n\n* ①Severe thrombosis or cavernous degeneration in the portal vein system, and liver transplantation is contraindicated upon evaluation;\n\n  * Hepatic encephalopathy stage IV;\n\n    * Pulmonary arterial hypertension (moderate to high risk, WHO grade III-IV) that does not improve after medical treatment or is assessed to have contraindications for surgery; ④Special types of anatomical variations;\n\n      * Inability to tolerate surgical anesthesia (such as severe infection, cardiopulmonary insufficiency, cerebrovascular disease, etc.); ⑥Severe mental illness; ⑦Other reasons that the researcher believes are not suitable for participation.","75 Years",{"count":194,"type":20},47,[23],"Hepatitis B virus (HBV) infection is a very difficult public health problem in the world. Patients often experience the trilogy of \"hepatitis-cirrhosis-liver cancer\". Patients with decompensated cirrhosis may develop a variety of complications, such as portal hypertension, hypersplenism, esophageal and gastric variceal bleeding, ascites, spontaneous peritonitis, hepatic encephalopathy, etc.\n\nLiver transplantation is the only way to cure hepatitis B cirrhosis. However, the shortage of liver donors still severely limits its development. In 2015, Line and others proposed a new surgical method, namely resection and partial liver segment 2-3 transplantation with delayed total hepatectomy (RAPID). This surgery innovatively combines auxiliary liver transplantation and ALLPS surgery, which can greatly alleviate the problem of liver donor shortage and improve the overall prognosis of the above-mentioned patients.\n\nOur center has designed the Sequential Adult Left Lateral Liver Transplantation (SALT) procedure based on the principles of RAPID surgery and the characteristics of patients with cirrhosis. Compared with RAPID surgery, SALT surgery can dynamically monitor and regulate the blood flow of the residual liver and transplanted liver, reducing the risk caused by portal hypertension. This study will evaluate the safety and effectiveness of SALT in the treatment of post-hepatitis B cirrhosis.",[198,26],"Liver Cirrhosis","2023-11-22",{"date":201,"type":31},"2023-12-01",{"date":201,"type":20},{"date":204,"type":20},"2027-03-30",{"name":206,"class":38},"RenJi Hospital"]